1605313-15-2Relevant academic research and scientific papers
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmor
Johnson, Christopher N.,Ahn, Jong Sook,Buck, Ildiko M.,Chiarparin, Elisabetta,Day, James E. H.,Hopkins, Anna,Howard, Steven,Lewis, Edward J.,Martins, Vanessa,Millemaggi, Alessia,Munck, Joanne M.,Page, Lee W.,Peakman, Torren,Reader, Michael,Rich, Sharna J.,Saxty, Gordon,Smyth, Tomoko,Thompson, Neil T.,Ward, George A.,Williams, Pamela A.,Wilsher, Nicola E.,Chessari, Gianni
, p. 7314 - 7329 (2018/09/06)
Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis. Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in
BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
-
, (2014/05/07)
The invention relates to new bicyclic heterocycle compounds of formula (I): (Formula (I)), pharmaceutical compositions comprising said compounds and to use of said compounds in the treatment of diseases, e.g. cancer.
BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
-
, (2014/05/07)
The invention relates to new bicyclic heterocycle compounds of formula (I):,to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
